Vernalis plc to Present at UBS Global Life Sciences Conference on September 26, 2006
20 September 2006
WINNERSH, U.K., September 20, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), a specialty bio-pharmaceutical and drug development company, today announced that Simon Sturge, Chief Executive Officer, and Tony Weir, Chief Financial Officer, will participate in the UBS Global Life Sciences Conference to be held September 25-28, 2006 at the Grand Hyatt in New York City. Mr. Sturge is scheduled to present an overview of the Company’s business activities and product pipeline at 8:00 AM Eastern time on Tuesday, September 26, 2006.
To listen to the audio webcast of the presentation, please visit: www.ibb.ubs.com.
About Vernalis
Vernalis is a speciality bio-pharmaceutical company focused on
products marketed to specialist neurologists. The company has two
marketed products, Frova® and Apokyn®, and a development
pipeline focused on neurology and central nervous system disorders.
The company has seven products in clinical development and
collaborations with leading, global pharmaceutical companies
including Novartis, Biogen Idec and Serono. Vernalis has
established a US commercial operation to promote Apokyn® and
co-promote Frova® alongside its North American licensing
partner, Endo Pharmaceuticals, progressing the company towards its
goal of becoming a sustainable, self-funding, R&D-driven,
speciality bio-pharmaceutical company. For further information
about Vernalis, please visit www.vernalis.com.
-- ends --
Enquiries:
| Vernalis plc | +44 (0) 118 977 3133 |
| Simon Sturge, Chief Executive Officer | |
| Tony Weir, Chief Financial Officer | |
| Julia Wilson, Head of Corporate Communications | |
| Lazar Partners Ltd | |
| Gregory Gin | 212-867-1762 |
Vernalis Forward-Looking Statement
This news release may contain forward-looking statements that
reflect the Company’s current expectations regarding future
events including the clinical development and regulatory clearance
of the Company’s products and including that of Frova®
for menstrual migraine, the Company’s ability to find
partners for the development and commercialisation of its products,
the benefits of re-acquiring Frova® in North America and the
partnership with Endo on the Company’s liquidity and results
of operations, as well as the Company’s future capital
raising activities. Forward-looking statements involve risks and
uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors including the
success of the Company’s research strategies, the
applicability of the discoveries made therein, the successful and
timely completion of clinical studies, including with respect to
Frova® and the Company’s other products, the
uncertainties related to the regulatory process, the ability of the
Company to identify and agree beneficial terms with suitable
partners for the commercialisation and/or development of Frova®
and other products, as well as the achievement of expected
synergies from such transactions, the acceptance of Frova® and
other products by consumers and medical professionals, the
successful integration of completed mergers and acquisitions and
achievement of expected synergies from such transactions, and the
ability of the Company to identify and consummate suitable
strategic and business combination transactions.
